PipelineReview.com - Target Pipelines

Show Cart

Target Pipelines

Results 21 - 30 of 67

Jul 2018 Adenosine Pathway Modulation via A2AR, CD39 & CD73 – Target Pipeline List 07/2018

Jul 2018 B7-H3 Immune Checkpoint Inhibitors - Target Pipeline List 07/2018

Jul 2018 CD40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 GITR Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 OX40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 CD27 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 ICOS Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 PD-1 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 PD-L1 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 CTLA-4 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing